Medscape
Univadis
Medscape
Univadis
No Results
No Results
Miriam E. Tucker, for Medscape
January 18, 2023
The study covered in this summary was published in Research Square as a preprint and has not yet been peer reviewed.
Nearly two thirds of Brazilian study participants with childhood-onset type 1 diabetes had residual pancreatic beta-cell function — as indicated by some detectable C-peptide function — more than 3 years after diagnosis.
Even this minimal detectable C-peptide level appeared to protect against albuminuria regardless of A1c or diabetes duration.
The relationship between residual beta-cell function and chronic diabetes complications isn’t clear.
Cross-sectional observational study with 138 adults (58.7% men) with type 1 diabetes for 3 years or longer.
Mean age at type 1 diabetes diagnosis was 9 years, median age at study start was 26 years, diabetes duration was 17 years, and mean A1c was 67 mmol/mol (8.3%).
Clinical variables, metabolic variables, and microvascular complications were compared between 59.4% of participants with some detectable C-peptide (defined as ultra-sensitive fasting serum C-peptide > 1.15 pmol/L; FCP+) and 40.6% of participants with no detectable C-peptide (< 1.15 pmol/L; FCP-).
Nephropathy was present in 19.6% of total participants, at 13.4% for FCP+ versus 28.6% for FCP- (P = .03).
There were no significant differences in neuropathy (2.9% total, 2.4% FCP+, 3.6% FCP-; P = 1.0) or retinopathy (3.6% total, 2.4% FCP+, 5.4% FCP-; P = .3).
There was a significant positive association between FCP+ and age at type 1 diabetes diagnosis (P = .039) and a significant negative association with disease duration (P = .002).
The probabilities of being FCP+ at 5, 10, and 20 years after type 1 diabetes diagnosis were 75%, 64.5%, and < 50%, respectively.
Each year of increased diabetes duration corresponded with an 8% reduction in the probability of being FCP+ (odds ratio, 0.92).
After adjustment for covariates, there was a lower prevalence of albuminuria among those who were FCP+ versus FCP- (13.4% vs 28.6%; P = .031).
Participants without nephropathy were 2.5 times more likely to be FCP+ than those with nephropathy.
Small sample size.
Cross-sectional data.
Use of FCP rather than stimulated C-peptide.
Low prevalence of chronic complications.
Study funding: None.
Author disclosures: None.
This is a summary of a preprint research study, “Residual β-cell function in long-duration Brazilian type 1 diabetes is associated with a low prevalence of nephropathy,“ by Monica Andrade, Federal University of São Paulo, Brazil, and colleagues. The study has not yet been peer reviewed.
Credits:
Lead image: iStock/Getty Images
© 2023 WebMD, LLC
Send comments and news tips to news@medscape.net.
Cite this: Residual Beta-Cell Function May Protect Kidneys in Type 1 Diabetes – Medscape – Jan 18, 2023.
Freelance writer, Medscape
Disclosure: Miriam E. Tucker has disclosed no relevant financial relationships.
You have already selected for My Alerts
Click the topic below to receive emails when new articles are available.
You’ve successfully added to your alerts. You will receive email when new content is published.
processing….